Do Δ9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?: RESEARCH REPORT

Addiction

Volumn 104, Issue 12, 2009, Pages 2041-2048

  Karschner, Erin L ^a   Schwilke, Eugene W ^a   Lowe, Ross H ^a   Darwin, W David ^a   Pope, Harrison G ^a,b   Herning, Ronald ^a   Cadet, Jean L ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Blood; Cannabinoids; Cannabis; Chronic use; Driving; Tetrahydrocannabinol

Indexed keywords

DRONABINOL; BIOLOGICAL MARKER; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; BLOOD; METHODOLOGY; MIDDLE AGED; SUBSTANCE ABUSE;

ADULT; BIOLOGICAL MARKERS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PSYCHOTROPIC DRUGS; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 70449393586     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02705.x     Document Type: Article

References (45)

1. Huestis M. A., Gorelick D. A., Heishman S. J., Preston K. L., Nelson R. A., Moolchan E. T. et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001 58 : 322 330.
2. Perez-Reyes M., Timmons M. C., Lipton M. A., Davis K. H., Wall M. E. Intravenous injection in man of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol. Science 1972 177 : 633 635.
3. Bland T. M., Haining R. L., Tracy T. S., Callery P. S. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005 70 : 1096 1103.
4. Watanabe K., Yamaori S., Funahashi T., Kimura T., Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007 80 : 1415 1419.
5. Wall M. E., Sadler B. M., Brine D., Taylor H., Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983 34 : 352 363.
6. Huestis M. A., Henningfield J. E., Cone E. J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992 16 : 276 282.
7. Huestis M. A., Henningfield J. E., Cone E. J. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta- 9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992 16 : 283 290.
8. Huestis M. A., Elsohly M., Nebro W., Barnes A., Gustafson R. A., Smith M. L. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther Drug Monit 2006 28 : 540 544.
9. Huestis M. A., Barnes A., Smith M. L. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy- delta9-tetrahydrocannabinol concentrations. Clin Chem 2005 51 : 2289 2295.
10. Ramaekers J. G., Berghaus G., Van Laar M., Drummer O. H. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004 73 : 109 119.
11. Block R. I., Farinpour R., Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. Pharmacol Biochem Behav 1992 43 : 907 917.
12. Chait L. D., Perry J. L. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology (Berl) 1994 115 : 340 349.
13. Riedel G., Davies S. N. Cannabinoid function in learning, memory and plasticity. In : Pertwee R. G., editor. Handbook of Experimental Pharmacology. New York : Springer 2005, p. 446 470.
14. Hall W., Solowij N. Adverse effects of cannabis. Lancet 1998 352 : 1611 1616.
15. Hampson R. E., Deadwyler S. A. Cannabinoids, hippocampal function and memory. Life Sci 1999 65 : 715 723.
16. Pope H. G., Gruber A. J., Hudson J. I., Huestis M. A., Yurgelun-Todd D. Cognitive measures in long-term cannabis users. J Clin Pharmacol 2002 42 : 41S 47S.
17. Pope H., Gruber A., Hudson J., Huestis M., Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001 58 : 909 915.
18. Peat M. A. Distribution of delta-9-tetrahydrocannabinol and its metabolites. In : Baselt, R. C., editor. Advances in Analytical Toxicology II. Chicago : Year Book Medical Publishers 1989, P. 186 217.
19. Skopp G., Potsch L. Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking. J Anal Toxicol 2008 32 : 160 164.
20. Lowe R. H., Karschner E. L., Schwilke E. W., Barnes A. J., Huestis M. A. Simultaneous quantification of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC), and 11-nor-delta-9- tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A 2007 1163 : 318 327.
21. Johansson E., Agurell S., Hollister L. E., Halldin M. M. Prolonged apparent half-life of delta-1-tetrahydrocannabinol in plasma of chronic marijuana users. J Pharm Pharmacol 1988 40 : 374 375.
22. Frytak S., Moertel C. G., Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep 1984 68 : 1427 1431.
23. Ellis G. M., Mann M. A., Judson B. A., Schramm N. T., Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985 38 : 572 578.
24. Dackis C. A., Pottash A. I. C., Annitto W., Gold M. S. Persistence of urinary marijuana levels after supervised abstinence. Am J Psychiatry 1982 139 : 1196 1198.
25. Cridland J. S., Rottanburg D., Robins A. H. Apparent half-life of excretion of cannabinoids in man. Hum Toxicol 1983 2 : 641 644.
26. Goodwin R. S., Darwin W. D., Chiang C. N., Shih M., Li S.-H., Huestis M. A. Urinary elimination of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008 32 : 562 566.
27. Darwin W. D., Herning R. I., Bolla K., Cadet J. L., Huestis M. A. A comparison by gender of urinary elimination of 11-nor-9-carboxy-Δ9- tetrahydrocannnabinol (THCCOOH) in cannabis users. Paper presented at the Society of Forensic Toxicologists Annual Meeting-2007, Durham, NC, 15-19 October, 2007.
28. Terhune K. W., Fell J. C. The Role of Alcohol, Marijuana, and Other Drugs in the Accidents of Injured Drivers. Washington, D.C. : US Department of Transportation, 1982.
29. Terhune K. W., Ippolito D. L., Hendricks D. L., Michalovic J. G., Bogema S. C., Santinga P. et al. The Incidence and Role of Drugs in Fatally Injured Drivers. October, 1-K1. Washington, D.C. : US Department of Transportation/ National Highway Traffic Safety Administration, 1992.
30. Williams A. F., Peat M. A., Crouch D. J., Wells J. K., Finkle B. S. Drugs in fatally injured young male drivers. Public Health Rep 1985 100 : 19 25.
31. Drummer O. H. Drugs in Drivers Killed in Australian Road Traffic Accidents. Victoria, Australia : Victorian Institute of Forensic Medicine, 1994.
32. Hunter C. E., Loken R. J., Longo M. C. The prevalence and role of alcohol, cannabinoids, benzodiazepines and stimulants in non-fatal crashes. S Austr Forensic Sci 1998.
33. Lowenstein S. R., Koziol-Mclain J. Drugs and traffic crash responsibility: a study of injured motorists in Colorado. J Trauma Inj Infect Crit Care 2001 50 : 313 320.
34. Drummer O. H., Gerostamoulos J., Batziris H., Chu M., Caplehorn J., Robertson M. D. et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 2004 36 : 239 248.
35. Ramaekers J. G., Moeller M. R., Van Ruitenbeek P., Theunissen E. L., Schneider E., Kauert G. Cognition and motor control as a function of delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 2006 85 : 114 122.
36. Grotenhermen F., Leson G., Berghaus G., Drummer O. H., Kruger H. P., Longo M. et al. Developing limits for driving under cannabis. Addiction 2007 102 : 1910 1917.
37. Jones A. W., Holmgren A., Kugelberg F. C. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood. Addiction 2008 103 : 452 461. (Pubitemid 351208103)
38. Christophersen A. S. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 1986 10 : 129 131.
39. Johnson J. R., Jennison T. A., Peat M. A., Foltz R. L. Stability of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 1984 8 : 202 204.
40. Wong A. S., Orbanosky M. W., Reeve V. C., Beede J. D. Stability of delta-9-tetrahydrocannabinol in stored blood and serum In : Hawks R., editor. Analysis of Cannabinoids, Research Monograph. Rockville, MD : National Institute on Drug Abuse, p. 119 124.
41. Schwilke E. W., Karschner E. L., Lowe R. H., Gordon A. M., Cadet J. L., Herning R. et al. Intra- and inter-subject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact-gas chromatography, mass spectrometry with cryofocusing. Clin Chem 2009 55 : 1188 1195.
42. Pope H. G., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996 275 : 521 527.
43. Bolla K. I., Brown K., Eldreth D., Tate K., Cadet J. L. Dose-related neurocognitive effects of marijuana use. Neurology 2002 59 : 1337 1343.
44. Solowij N., Stephens R. S., Roffman R. A., Babor T., Kadden R., Miller M. et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002 287 : 1123 1131.
45. Mura P., Kintz P., Dumestre V., Raul S., Hauet T. THC can be detected in brain while absent in blood. J Anal Toxicol 2005 29 : 842 843.